Equities

Mochida Pharmaceutical Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Mochida Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)3,670.00
  • Today's Change-45.00 / -1.21%
  • Shares traded32.30k
  • 1 Year change+13.80%
  • Beta0.2406
Data delayed at least 15 minutes, as of Feb 17 2026 06:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Mochida Pharmaceutical Co Ltd is a Japan-based company principally engaged in the production and sale of drugs. The Pharmaceutical-related segment is engaged in the manufacture, purchase and sale of pharmaceutical products. The Company also conducts brokerage and management of real estate properties, the maintenance and management of buildings, the agency of personal affairs, accounting and purchasing businesses. The Healthcare segment is involved in the manufacture, purchase and sale of quasi drugs and cosmetic products.

  • Revenue in JPY (TTM)111.92bn
  • Net income in JPY6.42bn
  • Incorporated1945
  • Employees1.51k
  • Location
    Mochida Pharmaceutical Co Ltd1-7, YotsuyaSHINJUKU-KU 160-8515JapanJPN
  • Phone+81 333587211
  • Fax+81 333587887
  • Websitehttps://www.mochida.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Oncolys Biopharma Inc28.55m-2.06bn70.07bn35.00--17.51--2,454.48-80.66-80.661.11136.640.00740.000.1004---53.08-53.26-58.54-60.190.00---7,209.58-484.939.54-424.600.0741---9.04-38.10-22.16--2.22--
ASKA Pharmaceutical Holdings Co Ltd68.70bn4.91bn72.63bn1.63k14.601.049.371.06172.92172.922,421.072,420.680.67291.373.6242,094,980.004.935.506.647.0748.3347.567.327.981.2375.350.155116.602.064.07-32.3951.049.4931.48
Nxera Pharma Co Ltd29.62bn-12.53bn84.52bn374.00--1.39--2.85-138.60-138.60328.05674.040.20690.81444.11---8.75-3.79-9.90-4.1672.3280.12-42.31-22.171.90-1.300.4847--2.7127.35-158.99--42.87--
JCR Pharmaceuticals Co Ltd37.55bn-2.44bn85.98bn987.00--1.75184.912.29-19.98-19.98307.86379.760.34320.45342.5038,039,510.00-2.215.86-3.779.3370.4573.83-6.4513.600.668--0.529545.13-22.865.94-186.42--15.3720.11
Cuorips Inc355.69m-764.60m90.51bn56.00--18.03--254.45-93.30-93.3043.60607.390.06563.33238.006,351,607.00-14.20---14.62--76.69---216.57--36.81--0.00--658.40---1.92------
Kyorin Pharmaceutical Co Ltd133.26bn10.77bn99.93bn2.00k8.900.68966.490.7499187.40187.402,319.592,417.370.69271.082.9366,695,200.005.603.347.034.1645.3245.898.085.112.05--0.174657.348.833.4170.738.1214.36-7.06
Katakura Industries Co Ltd40.98bn5.84bn110.93bn941.0017.281.1012.612.71182.30182.301,278.512,853.060.29262.156.4243,545,160.004.272.605.203.5736.1637.9814.599.442.63--0.080723.42-1.37-2.1915.7315.27-7.2233.03
Zeria Pharmaceutical Co Ltd86.61bn7.26bn111.08bn1.75k13.190.99767.631.28164.79164.791,964.972,178.210.53661.273.2149,607,640.004.494.676.997.4772.7672.178.379.020.973911.410.298428.7515.307.6428.5227.7116.516.69
Mochida Pharmaceutical Co Ltd111.92bn6.42bn135.19bn1.51k20.510.958314.401.21181.16181.163,156.953,876.770.64271.673.0274,214,190.003.694.504.475.4448.4352.495.746.872.85--0.067843.012.210.651625.034.341.980.00
Kaken Pharmaceutical Co Ltd75.66bn-3.83bn186.71bn1.13k--1.10--2.47-97.11-97.111,980.563,850.390.40911.862.8067,195,380.00-2.075.99-2.426.8753.0956.17-5.0612.913.21--0.025759.5830.521.0573.77-6.3614.810.00
Data as of Feb 17 2026. Currency figures normalised to Mochida Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

9.00%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 04 Feb 2026808.92k2.22%
Nomura Asset Management Co., Ltd.as of 05 Feb 2026756.90k2.08%
Amova Asset Management Co., Ltd.as of 06 Feb 2026354.30k0.97%
Daiwa Asset Management Co. Ltd.as of 30 Jan 2026339.00k0.93%
BlackRock Fund Advisorsas of 06 Feb 2026322.20k0.89%
Dimensional Fund Advisors LPas of 05 Feb 2026205.82k0.57%
Norges Bank Investment Managementas of 30 Jun 2025171.66k0.47%
Mitsubishi UFJ Asset Management Co., Ltd.as of 22 Jul 2024139.20k0.38%
Charles Schwab Investment Management, Inc.as of 05 Feb 202697.55k0.27%
BlackRock Advisors (UK) Ltd.as of 05 Feb 202679.30k0.22%
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.